医学
肝细胞癌
经导管动脉化疗栓塞
毒性
内科学
胃肠病学
胆红素
癌
放射科
作者
Lu Wu,Yefa Yang,Naijian Ge,Shuqun Shen,Jun Liang,Yi Wang,Weiping Zhou,Feng Shen,Mengchao Wu
出处
期刊:Cancer Biotherapy and Radiopharmaceuticals
[Mary Ann Liebert]
日期:2010-12-01
卷期号:25 (6): 657-663
被引量:24
标识
DOI:10.1089/cbr.2010.0801
摘要
Few options are available to treat patients with hepatocellular carcinoma (HCC). It was tested whether the combination of iodine-131(131I)-metuximab with chemoembolization could improve outcomes in patients with intermediate HCC. Between April 2008 and April 2009, 110 patients with unresectable HCC were treated with 113 intra-arterial 131I-metuximab injections combined with chemoembolization (mean, 1.03 per patient; median, 1; range, 1–2), followed by 264 sessions of transcatheter arterial chemoembolization (mean, 2.4 per patient; median, 3; range, 1–6). The survival rates at 6, 12, and 18 months were 88.2%, 79.1%, and 57.4%, respectively, by the Kaplan-Meier method. Of these patients, 12% exhibited grade 3/4 bilirubin toxicity, 5% exhibited grade 3/4 white blood count toxicity, and 7% exhibited grade 3/4 platelet toxicity. Response rates based on World Health Organization and European Association for the Study of the Liver criteria were 42.73% and 61.82%, respectively. The combination of 131I-metuximab and chemoembolization appeared to extend survival in patients with unresectable HCC compared with historical controls, as well as being well tolerated by patients with Child-Pugh A and B. This combination may represent a promising treatment modality for patients with intermediate HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI